The Vitamin D Resistance Mystery

Overview

The standard diagnostic paradigm employed by the National Health Service (NHS) regarding secalciferol metabolism is failing a significant cohort of patients presenting with classic musculoskeletal and neurocognitive symptoms of hypovitaminosis. Clinicians routinely rely on serum 25-hydroxyvitamin D [25(OH)D] assays as the definitive biochemical biomarker for status evaluation. However, this serum-centric approach creates a dangerous diagnostic blind spot. It fundamentally mistakes circulating substrate pool availability for downstream biological activity, ignoring the complex landscape of receptor-mediated hormone resistance. At INNERSTANDIN, our analysis of emerging endocrinological literature reveals that normal or even supranormal circulating 25(OH)D levels frequently coexist with profound intracellular vitamin D deficiency. This disconnect is driven by functional polymorphisms within the vitamin D receptor (VDR) gene, dysfunctional nuclear translocation machinery, and systemic upregulation of counter-regulatory enzymes like CYP24A1, which prematurely catabolise active hormonal metabolites. Consequently, patients presenting with intractable fatigue, osteomalacia-like bone pain, and immune dysregulation are repeatedly misdiagnosed with chronic fatigue syndrome, fibromyalgia, or psychosomatic somatic symptom disorders. NHS reference ranges, which anchor sufficiency at concentrations above 50 nmol/L, are epidemiologically derived based on parathyroid hormone suppression rather than optimal genomic saturation of the VDR across diverse peripheral tissues. When a patient exhibits textbook phenotypic manifestations of deficiency yet returns a serum assay within the laboratory reference range, general practitioners and endocrinologists routinely dismiss the clinical presentation as non-nutritional. This oversight halts further diagnostic interrogation into receptor insensitivity or transport protein anomalies, leaving the underlying molecular pathology unaddressed. Furthermore, chronic low-grade systemic inflammation—ubiquitous in modern UK populations due to dietary shifts and environmental stressors—upregulates pro-inflammatory cytokines such as tumour necrosis factor-alpha and interleukin-1 beta. These cytokines actively suppress VDR expression in target tissues, effectively inducing an acquired state of cellular hormone resistance. The systemic impact of this diagnostic failure is profound; patients are subjected to years of pharmacological mismanagement, ineffective high-dose cholecalciferol supplementation that fails to cross the resistant receptor threshold, and a cascading loss of physiological function. Resolving this clinical impasse requires a fundamental paradigm shift across UK healthcare institutions: moving away from crude serum pool quantification and toward an integrated assessment of cellular receptor dynamics, co-activator expression, and functional downstream gene transcription. Only by acknowledging the physiological reality of functional VDR resistance can the medical establishment dismantle the systemic misdiagnosis patterns currently compromising patient outcomes nationwide.

The Biology — How It Works

At the core of the vitamin D resistance paradigm lies a fundamental biochemical dissociation between circulating 25-hydroxyvitamin D [25(OH)D] and intracellular genomic action. To INNERSTANDIN this molecular failure, one must first dissect the classical endocrine and intracrine pathways governing cholecalciferol metabolism. Dietary intake or cutaneous synthesis yields inactive precursors that undergo hepatic hydroxylation via cytochrome P450 enzymes—primarily CYP2R1—to form 25(OH)D, the standard clinical biomarker measured in NHS biochemistry laboratories. However, circulating abundance does not equate to downstream biological efficacy. Upon reaching target peripheral tissues, 25(OH)D must traverse the cell membrane, often aided by megalin-cubilin receptor complexes, before undergoing a secondary, tightly regulated hydroxylation by CYP27B1 to produce the biologically potent ligand, 1,25-dihydroxyvitamin D [1,25(OH)₂D].

This active secosteroid subsequently binds with high affinity to the Vitamin D Receptor (VDR), a member of the nuclear receptor superfamily. Upon ligand binding, the VDR undergoes a conformational shift, heterodimerising with the Retinoid X Receptor (RXR). This functional heterodimer translocates to the nucleus, binding to specific Vitamin D Response Elements (VDREs) located within the promoter regions of hundreds of target genes. This complex epigenetic machinery recruits coregulator proteins—either histone acetyltransferases that promote chromatin unwinding and transcriptional activation, or corepressors that silence expression.

In states of clinical resistance, this intricate cascade is disrupted at multiple potential nodes. As documented in landmark molecular endocrinology literature published in journals such as The Lancet and The Journal of Clinical Endocrinology & Metabolism, resistance is rarely a binary failure of the receptor itself; rather, it is frequently secondary to chronic upregulation of intracellular inflammatory cytokines, particularly tumour necrosis factor-alpha (TNF-$\alpha$) and interleukin-1 beta (IL-1$\beta$). These pro-inflammatory cascades activate inhibitory transcription factors, such as nuclear factor kappa B (NF-$\kappa$B), which directly interfere with VDR-RXR heterodimerisation and compete for limiting coactivator reserves like SRC-1 and MED15. Furthermore, aberrant epigenetic hypermethylation of the VDR gene promoter region can drastically attenuate receptor density on the cell surface, even in the presence of supraphysiological circulating 25(OH)D.

Compounding this transcriptional blockade is the dysregulation of local catabolism. The enzyme CYP24A1 is responsible for degrading both 25(OH)D and 1,25(OH)₂D into inactive, excretory calcitroic acid. In resistant phenotypes, pathological upregulation of CYP24A1—often driven by persistent oxidative stress or aberrant fibroblast growth factor 23 (FGF23) signalling—creates a cellular sink that destroys the active ligand before genomic transcription can be initiated. Consequently, standard NHS reference ranges, which rely solely on serum 25(OH)D quantification, fail to capture this intracellular functional blockade. A patient may present with optimal or high-normal serum levels, yet experience profound tissue-level deficiency due to defective transmembrane transport, impaired renal or extrarenal CYP27B1 activation, VDR polymorphism-induced binding affinity loss, or excessive CYP24A1-mediated catabolism. This cellular disconnect underpins the systemic chronicity observed across autoimmune, metabolic, and neuroinflammatory pathologies in the UK population, demanding an immediate evolution in how clinical biochemistry interprets secosteroid utilisation.

Mechanisms at the Cellular Level

To comprehend why standard UK serum 25-hydroxyvitamin D [25(OH)D] assays frequently fail to reflect true tissue-level status, one must look beyond classical endocrine loops and examine the intricate cytopathology of functional vitamin D resistance. Within INNERSTANDIN’s rigorous analytical framework, we evaluate how aberrations at the cellular interface disrupt the biological cascades initiated by the active secosteroid, 1,25-dihydroxyvitamin D [1,25(OH)2D]. Standard clinical diagnostics rely on systemic ligand abundance, yet true cellular utilisation depends upon transmembrane transport, cytosolic trafficking, and nuclear receptor binding efficiency—variables largely invisible to conventional NHS pathology panels.

The primary molecular bottleneck frequently resides within the megalin-cubilin endocytic receptor complex, which is essential for the cellular uptake of circulating 25(OH)D bound to vitamin D-binding protein (DBP). In states of chronic low-grade systemic inflammation—prevalent across UK patient cohorts burdened by metabolic syndrome and autoimmune pathologies—pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-$\alpha$) and interleukin-6 (IL-6) downregulate megalin expression in proximal tubular cells and extra-renal target tissues. Consequently, even when serum 25(OH)D concentrations appear within the ostensibly 'sufficient' range of 50 to 75 nmol/L, target cells remain starved of the necessary substrate because receptor-mediated endocytosis is severely impaired.

Furthermore, intracellular bioactivation is governed by the sites of local expression for CYP27B1 (1-$\alpha$-hydroxylase) and CYP24A1 (24-hydroxylase). Under normal physiological parameters, extra-renal tissues—including macrophages, osteoblasts, and mucosal epithelial cells—autonomously convert intracellular 25(OH)D into 1,25(OH)2D to act in an intracrine and paracrine fashion. However, epigenetic silencing of the CYP27B1 promoter, driven by persistent oxidative stress and hyperhomocysteinemia, arrests this intracellular conversion. Concurrently, upregulated peroxisome proliferator-activated receptor gamma (PPAR-$\gamma$) signaling can aberrantly accelerate catabolism via premature induction of CYP24A1, degrading the secosteroid into inactive, excretory calcitroic acid before genomic transcriptional responses can be elicited.

At the nuclear architecture level, binding of 1,25(OH)2D to the vitamin D receptor (VDR) requires heterodimerisation with the retinoid X receptor (RXR) and the subsequent recruitment of specific coregulator complexes to vitamin D response elements (VDREs) on target genes. Genetic polymorphisms within the VDR gene—such as BsmI, FokI, TaqI, and ApaI—alongside acquired post-translational modifications like phosphorylation and O-GlcNAcylation, alter receptor conformation. This structural deviation prevents optimal recruitment of histone acetyltransferases, arresting chromatin remodelling and silencing downstream transcription of immunomodulatory and antimicrobial peptides like cathelicidin.

This multi-tiered cellular decoupling explains the clinical paradox frequently observed in UK general practice: patients presenting with classic musculoskeletal pain, profound fatigue, and dysregulated immune parameters despite replete serum biochemistry. By dissecting these cytopathological mechanisms, INNERSTANDIN reveals that functional resistance is rarely a failure of dietary intake, but rather a profound molecular discoordination within the cellular machinery itself.

Environmental Threats and Biological Disruptors

To fully comprehend the persistent diagnostic blind spots within the British healthcare framework, one must move past the reductionist view that vitamin D status is dictated solely by cutaneous synthesis and dietary intake. At INNERSTANDIN, our translational analysis reveals a more complex etiology: the functional decoupling of the vitamin D receptor (VDR) and its downstream genomic machinery driven by environmental xenobiotics and contemporary biochemical stressors. This uncoupling explains why standard National Health Service assays frequently categorize patients as biochemically replete while they simultaneously manifest profound, systemic manifestations of cellular vitamin D starvation.

Industrialized populations are continuously exposed to endocrine-disrupting chemicals (EDCs) that directly sabotage nuclear receptor signalling pathways. Polychlorinated biphenyls (PCBs), phthalates, and persistent organic pollutants—ubiquitous within the modern British urban and agricultural environment—act as potent agonists or antagonists at the pregnane X receptor (PXR) and the constitutive androstane receptor (CAR). Activation of PXR by these xenobiotics upregulates the transcription of cytochrome P450 enzymes, specifically CYP24A1, which accelerates the catabolism of both 25-hydroxyvitamin D [25(OH)D] and the active hormone 1,25-dihydroxyvitamin D [1,25(OH)₂D] into inactive calcitroic acid. Consequently, systemic clearance of the secosteroid is hyper-accelerated, rendering circulating metabolites functionally obsolete before they can engage their target tissues.

Simultaneously, the modern exposome inflicts chronic, low-grade oxidative stress that induces epigenetic silencing of the VDR gene (VDR). Environmental toxins, particulate matter (PM2.5), and heavy metal accumulation trigger nuclear factor kappa B (NF-$\kappa$B) activation, which subsequently promotes histone deacetylase (HDAC) recruitment to the VDR promoter region. This epigenetic modification compacts chromatin architecture, downregulating VDR density on peripheral immune cells, enterocytes, and osteoblasts. Even when serum 25(OH)D levels appear adequate on a standard pathology report, the blunted receptor reserve precludes canonical vitamin D response element (VDRE) activation. The cell is rendered functionally blind to the hormone, arresting autocrine and paracrine immune modulation, epithelial barrier maintenance, and bone remodelling.

Compounding this xenobiotic burden is the pervasive impact of glyphosate and other agrochemical residues on the human microbiome and hepatic enzyme kinetics. Research published in peer-reviewed toxicology literature demonstrates that glyphosate chelates divalent cations essential for enzymatic function and disrupts the cytochrome P450 superfamily in the liver. This inhibition cripples hepatic 25-hydroxylase activity (CYP2R1), preventing the primary bioactivation step of cholecalciferol regardless of supplementation compliance. Furthermore, dysbiosis induced by dietary emulsifiers and xenobiotics compromises short-chain fatty acid (SCFA) production, particularly butyrate, which acts as a natural endogenous HDAC inhibitor necessary for maintaining open chromatin states at vitamin D target loci.

When these multifactorial environmental insults converge within the British populace, they generate a clinical paradox: a population-wide resistance syndrome masquerading as simple deficiency. Standard NHS diagnostic pathways measure only circulating pool volume, completely blind to the functional integrity of the VDR and the catabolic overdrive enforced by the chemical exposome. Resolving this diagnostic failure requires the scientific community to pivot from static serum quantification to dynamic, systems-level assessments of receptor sensitivity and xenobiotic load, aligning clinical practice with the biological reality mapped by contemporary molecular research.

The Cascade: From Exposure to Disease

At the core of the diagnostic failures pervading contemporary UK clinical practice lies a fundamental misunderstanding of the endocrinological cascade that converts cutaneous ultraviolet radiation into genomic transcriptional regulation. When 7-dehydrocholesterol in the epidermal stratum basale absorbs UVB photons (290–315 nm), it undergoes thermal isomerisation to previtamin D3, subsequently thermalising into cholecalciferol. However, in cohorts presenting with the vitamin D resistance phenotype, this initiating photobiological step is entirely decoupled from downstream physiological utilisation. Standard NHS diagnostic pathways—heavily reliant on serum 25-hydroxyvitamin D [25(OH)D] assays—fundamentally fail here, as they measure circulating substrate availability rather than intracellular bioenergetic signaling efficacy. As documented in biochemical literature via PubMed-indexed analyses of nuclear receptor dynamics, an individual can present with replete, or even supraphysiological, serum 25(OH)D levels while simultaneously experiencing severe tissue-level starvation due to post-receptor signaling blocks.

Once cholecalciferol is hydroxylated in the hepatic parenchyma by CYP2R1 to form 25(OH)D, it must traverse the cell membrane via megalin-cubilin receptor-mediated endocytosis to undergo its final activation by renal and extra-renal 1α-hydroxylase (CYP27B1) into 1,25-dihydroxyvitamin D [1,25(OH)2D], the potent steroid hormone ligand for the Vitamin D Receptor (VDR). In cases of functional resistance, this cascade fractures. Genetic polymorphisms within the VDR gene—such as FokI, BsmI, ApaI, and TaqI restriction fragment length polymorphisms—or acquired epigenetic silencing of the retinoid X receptor (RXR) heterodimerisation partner, induce conformational rigidity within the VDR ligand-binding domain. Consequently, high-affinity binding of 1,25(OH)2D is abrogated. At INNERSTANDIN, our synthesis of molecular endocrinology reveals that this uncoupling prevents the recruitment of crucial co-activator complexes, stalling the transcriptional upregulation of over 900 target genes responsible for immune modulation, cellular differentiation, and calcium homeostasis.

The downstream pathological cascade of this receptor-level resistance manifests as a systemic, insidious deterioration. Without functional VDR-RXR nuclear translocation and subsequent vitamin D response element (VDRE) activation, innate immune cells—particularly macrophages and monocytes—fail to upregulate endogenous cathelicidin and defensin synthesis, rendering the patient clinically immunocompromised despite normal biochemical panels. Concurrently, the adaptive arm skews toward a pro-inflammatory Th1/Th17 cytokine profile, driving chronic, low-grade systemic inflammation akin to autoimmune diatheses. Furthermore, gastrointestinal active calcium transport via epithelial calcium channels (TRPV6) and calbindin-D9k remains downregulated, provoking secondary hyperparathyroidism as the parathyroid glands attempt to salvage systemic calcium homeostasis by resorbing the skeletal matrix.

This multi-systemic failure exposes a profound vulnerability in standard UK primary care protocols. By equating circulating 25(OH)D concentrations with biological health, clinicians routinely misdiagnose the manifestations of VDR resistance—ranging from treatment-refractory myalgia and chronic fatigue to accelerated osteopenia and immune dysregulation—as psychosomatic or idiopathic pathologies. True resolution demands a paradigm shift: moving away from crude substrate repletion strategies and toward personalized molecular profiling that interrogates receptor functionality, co-factor availability, and intracellular signal transduction cascades.

What the Mainstream Narrative Omits

Standard clinical endocrinology within the National Health Service remains stubbornly anchored to an archaic diagnostic paradigm, evaluating systemic health almost exclusively via circulating serum 25-hydroxyvitamin D [25(OH)D] concentrations. This reductionist approach fundamentally misinterprets the complex biochemical realities governing nuclear receptor kinetics and intracrine signaling. As extensively documented in literature from The Lancet and PubMed-indexed molecular endocrinology repositories, a normal or even optimized serum 25(OH)D level does not guarantee adequate biological activity at the tissue level. The mainstream clinical narrative systematically omits the critical distinction between circulating vitamin D availability and cellular-level hormone utilization, setting the stage for widespread diagnostic oversight across UK primary and secondary care.

At the core of this resistance mystery lies the functional integrity of the Vitamin D Receptor (VDR) and its obligate heterodimerization partner, the retinoid X receptor (RXR). Polymorphisms within the VDR gene—such as BsmI, ApaI, TaqI, and FokI—frequently compromise ligand-binding affinity or downstream transcriptional efficiency. Furthermore, chronic pro-inflammatory cytokine milieus, characterized by elevated interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-$\alpha$), actively downregulate VDR expression and inhibit the hepatic and extra-renal conversion enzymes CYP27B1 and CYP24A1. Consequently, a patient presenting with classic symptoms of musculoskeletal pain, profound fatigue, and immune dysregulation may possess replete serum 25(OH)D levels while simultaneously experiencing severe intracellular vitamin D starvation.

By treating the serum pool as the definitive biomarker of vitamin D sufficiency, NHS diagnostic pathways routinely overlook acquired and genetic VDR resistance syndromes. Patients are frequently dismissed as having functional somatic syndromes or psychosomatic disorders when their pathology is, in fact, rooted in impaired genomic signaling. At INNERSTANDIN, our critical appraisal of this diagnostic blind spot reveals that true clinical resolution requires shifting the biomedical lens away from simple metabolite quantification and toward cellular responsiveness, co-factor availability, and receptor-level dynamics. Without this paradigm shift, thousands of British patients will continue to fall through the cracks of a dogmatic, outmoded healthcare framework that confuses circulating abundance with biological efficacy.

The UK Context

Within the United Kingdom, the diagnostic framework governing endocrine homeostasis remains stubbornly anchored to antiquated population-level thresholds, creating a systemic blind spot for Vitamin D resistance phenotypes. Epidemiological data published in The Lancet and indexed across PubMed consistently highlight that over one-fifth of the British populace exhibits sub-optimal serum 25-hydroxyvitamin D [25(OH)D] concentrations during winter months. However, the true pathological depth of the Vitamin D Resistance Mystery extends far beyond mere dietary insufficiency or insufficient solar ultraviolet-B (UVB) irradiance at latitudes above 50°N. NHS diagnostic pathways overwhelmingly rely on serum 25(OH)D quantification as the definitive biomarker of vitamin D status, fundamentally operating under the assumption that circulating ligand availability equates to intracellular receptor-mediated bioactivity. This reductionist paradigm ignores the complex upstream and downstream mechanics of nuclear receptor signalling, specifically the Vitamin D Receptor (VDR) and its mandatory heterodimerisation partner, the Retinoid X Receptor (RXR).

In British clinical practice, patients presenting with chronic musculoskeletal fatigue, cognitive fog, persistent myalgia, and secondary hyperparathyroidism are frequently misdiagnosed with fibromyalgia, chronic fatigue syndrome, or psychosomatic presentations. When standard assays return serum 25(OH)D levels within the laboratory reference range—often set at a permissive >50 nmol/L—clinicians routinely dismiss the hormone pathway as aetiologically irrelevant. This diagnostic oversight betrays a profound misunderstanding of molecular endocrinology at INNERSTANDIN. Resistance states frequently manifest not from ligand starvation, but from polymorphic variations within the VDR gene (such as BsmI, TaqI, ApaI, and FokI restrictions fragment lengths), epigenetic methylation silencing the promoter regions, or functional dysregulation of hepatic and extrarenal CYP27B1 hydroxylase enzymes. Furthermore, chronic low-grade systemic inflammation, highly prevalent in the UK population due to rising metabolic syndrome rates, upregulates pro-inflammatory cytokines like TNF-alpha and IL-1 beta. These cytokines competitively inhibit VDR expression and downregulate co-activator recruitment, effectively locking target tissues into a state of functional hormone insensitivity. Consequently, standard supplementation protocols yield negligible clinical amelioration, leaving British patients trapped in a diagnostic loop where physiological resistance is routinely mislabelled as normal variant physiology or hypochondriasis.

Protective Measures and Recovery Protocols

Addressing functional vitamin D resistance—wherein systemic cholecalciferol or calcidiol pools appear adequate or even supranormal on standard pathology assays yet cellular utilisation remains critically impaired—demands a paradigm shift away from passive supplementation toward targeted receptor upregulation and cofactor optimisation. As established in recent pharmacokinetic reviews published in The Lancet and indexed via PubMed, standard UK clinical pathways rely predominantly on serum 25-hydroxyvitamin D [25(OH)D] thresholds, frequently failing to identify intracellular blockade at the vitamin D receptor (VDR) or downstream heterodimerisation steps with the retinoid X receptor (RXR). For patients navigating the NHS diagnostic labyrinth, this often translates to protracted chronicity of autoimmune, inflammatory, and neurocognitive pathologies due to unrecognised resistance phenotypes driven by chronic immune activation, cytokine-mediated VDR downregulation, and epigenetic silencing.

To counteract these intricate mechanisms, therapeutic recovery protocols must first dismantle the inflammatory architecture suppressing receptor sensitivity. Pro-inflammatory cytokines, particularly tumour necrosis factor-alpha (TNF-$\alpha$) and interleukin-1 beta (IL-1$\beta$), heavily downregulate VDR expression and inhibit 1$\alpha$-hydroxylase enzyme activity within target tissues. Clinical immunologists advocating for advanced biological resolution emphasise reducing systemic load through targeted immunomodulatory interventions and mitigating xenobiotic or microbial stressors that chronically trigger toll-like receptors (TLRs). At INNERSTANDIN, our synthesis of translational endocrinology highlights that flooding an unresponsive cellular matrix with high-dose cholecalciferol is biologically futile; instead, clinicians must restore intracellular signalling fidelity.

Optimising the enzymatic and cofactor cascade is equally paramount. The conversion of precursor molecules and the translocation of the activated hormone-receptor complex into the nucleus rely on an array of synergistic micronutrients. Magnesium acts as an essential cofactor for all enzymes involved in vitamin D metabolism, functioning as a critical structural component for both 25-hydroxylase and 1$\alpha$-hydroxylase enzymes. Clinical observations indicate that subclinical magnesium deficiency—rampant within Western dietary paradigms—renders standard supplementation ineffective, as the catalytic machinery cannot process the sterol rings. Furthermore, adequate intracellular status of vitamin K2 (specifically the MK-7 menaquinone isoform) must be secured to direct downstream transcriptional targets, ensuring calcium is properly channelled via osteocalcin while preventing soft tissue calcification induced by aberrant VDR signalling.

Finally, tackling epigenetic modifications that silence the VDR gene requires addressing methylation imbalances and oxidative stress. Upregulating endogenous antioxidant defenses via nuclear factor erythroid 2-related factor 2 (Nrf2) pathways helps restore the redox balance necessary for optimal RXR-VDR heterodimerisation. By integrating precision diagnostics that evaluate functional cellular response rather than static serum pools, clinicians can move beyond obsolete NHS misdiagnosis patterns. Implementing these multi-systemic recovery protocols allows patients trapped in the vitamin D resistance loop to re-establish genomic stability, recalibrate innate and adaptive immunity, and recover true metabolic homeostasis.

Summary: Key Takeaways

The pervasive clinical assumption that serum 25-hydroxyvitamin D [25(OH)D] sufficiency equates to functional metabolic repletion represents a profound diagnostic failure within UK primary care. As synthesised throughout this investigation, true Vitamin D resistance is fundamentally rooted in cellular-level dysregulation—specifically, polymorphisms within the Vitamin D Receptor (VDR), dysfunctional co-activator recruitment, and acquired intracellular transport blocks—rather than mere dietary deficiency or inadequate solar ultraviolet-B exposure at northern latitudes. Standard NHS assessment paradigms rely almost exclusively on circulating endocrine biomarkers, systematically overlooking downstream intracrine and paracrine signalling failures. Consequently, patients presenting with profound musculoskeletal pain, neurocognitive fog, and upregulated systemic inflammation are frequently misdiagnosed with chronic fatigue syndrome or fibromyalgia. As peer-reviewed literature indexed in PubMed and The Lancet demonstrates, bypassing these molecular bottlenecks requires abandoning crude bolus supplementation protocols in favour of precision immunometabolic profiling. INNERSTANDIN maintains that until clinical endocrinology integrates genomic receptor mapping and intracellular functional assays, millions of patients will remain pathologically trapped in a state of cellular starvation amidst biochemical abundance.